ISIS Pharmaceuticals (ISIS) is a dynamic biotechnology company focused on the development of antisense oligonucleotides (ASOs) as drugs. Its chief antisense oligonucleotide (ASO) is Kynamro (mipomersen), which is used to lower cholesterol. After reviewing available long-term data on Kynamro, I will show that Kynamro has qualities that make for a very poor drug because:
1. It is poorly tolerated.
2. It is immunogenic.
3. The immune response is associated with increased adverse events.
4. Long-term use leads to increased adverse events.
As acknowledged by ISIS CEO Stanley Crooke in a recent review, Kynamro (mipomersen) is a representative molecule of ISIS second generation antisense oligonucleotides (ASOs). He states:
Mipomersen is representative of second generation ASOs. As all ...